Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients
Official title: Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.
Run by Amsterdam UMC, location VUmc · NCT06644144 · Data updated 2026-11-12
This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Locations | 1 site (Amsterdam, North Holland) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | October 1, 2028 |
| Study ends | October 1, 2031 |
| Registry record updated | May 11, 2026 |
| Trial ID | NCT06644144 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 80 with a diagnosis of IPF, FPF, other fibrotic ILDs, or interstitial lung abnormalities.
✕Probably not a fit
Patients with combined pulmonary fibrosis and emphysema or chronic obstructive lung disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in adults diagnosed with various interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and familial pulmonary fibrosis (FPF). Participants will undergo multiple study visits over five years to collect clinical data and biological samples, allowing researchers to analyze risk factors and biomarkers associated with fibrosis progression and treatment response. The study will compare outcomes among different types of ILD to enhance understanding of disease progression.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification of patients at risk for rapid disease progression, allowing for timely interventions.
How similar studies have gone: While this approach is observational and builds on existing knowledge, similar studies have shown promise in identifying biomarkers for lung diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA). * Meeting all the following criteria during the screening period: 1. FVC ≥45% predicted. 2. FEV1/FVC ≥0.7. 3. DLco corrected for Hb ≥40% predicted. * Able to provide written informed consent as approved by the independent ethics committee. * Able to undergo a CT scan and perform PFT. * Age \> 18 years and \< 80 years. * Understanding of the Dutch or English language. Exclusion Criteria: * Combined pulmonary fibrosis and emphysema (CPFE) diagnosis * Chronic obstructive lung disease (COPD) with an FEV1/FVC \<70%. * Uncontrolled severe asthma. * Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer. * Pregnancy or lactating.
Where it's running
-
Amsterdam UMC, locatie VUmc
Amsterdam, North Holland, Netherlands Recruiting
Study contacts
- Principal investigator: Esther Nossent, MD — Amsterdam UMC, locatie VUmc
- Study coordinator: Jan Willem Duitman, PhD
- Email: j.w.duitman@amsterdamumc.nl
- Phone: 0205668753
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
Advanced imaging to see how immunosuppression affects lung fibrosis activity
This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.
-
Understanding genetic and environmental factors in pulmonary fibrosis
This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.
-
Using breath analysis to identify multiple lung diseases
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
-
Biobank for interstitial lung diseases
This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.
-
Registry for individuals affected by pulmonary fibrosis
This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.